Home
Drugs
Lenalidomide
Clinical Trials

Clinical Trials Related to Lenalidomide

Related studies linked through entity extraction aliases.

Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Status: RECRUITING
Phase: PHASE3

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

Status: NOT_YET_RECRUITING
Phase: PHASE2

A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Status: RECRUITING
Phase: PHASE2

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Status: NOT_YET_RECRUITING
Phase: PHASE2

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Status: RECRUITING
Phase: PHASE4

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Status: WITHDRAWN
Phase: PHASE2

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Status: RECRUITING
Phase: PHASE2/PHASE3

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Status: WITHDRAWN
Phase: PHASE3

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Status: RECRUITING
Phase: PHASE3

Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

Status: NOT_YET_RECRUITING
Phase: N/A

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

Status: RECRUITING
Phase: PHASE3

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Status: RECRUITING
Phase: EARLY_PHASE1

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Status: RECRUITING
Phase: PHASE2

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

Status: RECRUITING
Phase: PHASE2

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Status: RECRUITING
Phase: PHASE3